


# PRODUCT INFORMATION



## Digoxigenin Monodigitoxoside

Item No. 21699

**CAS Registry No.:** 5352-63-6  
**Formal Name:** (3 $\beta$ ,5 $\beta$ ,12 $\beta$ )-3-[(2,6-dideoxy- $\beta$ -D-ribohexopyranosyl)oxy]-12,14-dihydroxycard-20(22)-enolide  
**MF:** C<sub>29</sub>H<sub>44</sub>O<sub>8</sub>  
**FW:** 520.7  
**Purity:**  $\geq$ 90%  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:**  $\geq$ 4 years  
**Special Conditions:** Hygroscopic



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Digoxigenin monodigitoxoside is supplied as a solid. A stock solution may be made by dissolving the digoxigenin monodigitoxoside in the solvent of choice, which should be purged with an inert gas. Digoxigenin monodigitoxoside is slightly soluble in DMSO and methanol.

### Description

Digoxigenin monodigitoxoside is a Na<sup>+</sup>/K<sup>+</sup>-ATPase inhibitor and cardiac glycoside metabolite of digoxin (Item No. 22266).<sup>1</sup> It has a binding affinity of 0.829 and an inhibitory potency of 1.07 relative to [<sup>3</sup>H]ouabain in a competitive binding assay using purified lamb Na<sup>+</sup>/K<sup>+</sup>-ATPase and for its ATPase activity, respectively.<sup>2</sup> Digoxigenin monodigitoxoside is selective for the  $\alpha_3\beta_1$  isoform over  $\alpha_1\beta_1$  and  $\alpha_2\beta_1$  ( $K_d$ s = 31.8, 65, and 35 nM, respectively).<sup>3</sup> Digoxigenin monodigitoxoside produces a more potent inotropic response in perfused guinea pig hearts than digoxin with 60 and 46% increases in inotropy, respectively.<sup>1</sup>

### References

1. Stephen, P.M., Dutta, S., and Marks, B.H. The uptake and subcellular distribution of radio-labeled metabolites of digoxin in the isolated perfused guinea-pig heart. *Naunyn Schmiedebergs Arch. Pharmacol.* **292**(3), 251-254 (1976).
2. Paula, S., Tabet, M.R., and Ball, W.J., Jr. Interactions between cardiac glycosides and sodium/potassium-ATPase: Three-dimensional structure-activity relationship models for ligand binding to the E2-Pi form of the enzyme versus activity inhibition. *Biochemistry* **44**(2), 498-510 (2005).
3. Katz, A., Lifshitz, Y., Bab-Dinitz, E., *et al.* Selectivity of digitalis glycosides for isoforms of human Na,K-ATPase. *J. Biol. Chem.* **285**(25), 19582-19592 (2010).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/10/2024

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM